10:27 AM EDT, 03/10/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Monday it has agreed to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International for $36.5 million.

The facility includes manufacturing, laboratory, warehouse, and office space, the company said. It expects to close the sale in Q1.

Emergent will retain the rights to secure manufacturing services and capacity at the facility in partnership with Syngene as part of the deal, Emergent said.

Price: 5.73, Change: -0.04, Percent Change: -0.69